Track Royalty Pharma plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Royalty Pharma plc RPRX · Stock Open Royalty Pharma plc in new tab

69.31 USD
P/E
45.08
EPS
1.53
Yield
1.36%
Safety Score
72
P/B
4.50
ROE
12.09
Beta
0.36
Target Price
72.00 USD
Royalty Pharma plc logo

Royalty Pharma plc

🧾 Earnings Recap – Q3 2026

Royalty Pharma’s third-quarter results were broadly steady, with the stock up 1.7% after earnings. Receipts grew 9%, and the company raised 2026 guidance again, while the transcript also notes a disappointing Phase III outcome for pelacarsen.

  • Third-quarter Portfolio Receipts and Royalty Receipts each grew 9%; Royalty Receipts were up 12% year to date.
  • The company raised full-year 2026 guidance for the third consecutive quarter, citing business momentum.
  • Royalty Pharma had deployed $1.6 billion of capital year to date and returned close to $590 million to shareholders through dividends and share repurchases in the first nine months.
  • The company reported a 14.3% return on invested capital and a 20.2% return on invested equity.
  • Pelacarsen’s Phase III results disappointed; management said the investment was structured to recover the capital invested plus a small return.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 10, 2027
P/E45.08
EPS1.53
Book Value15.34
Price to Book4.50
Debt/Equity87.67
% Insiders6.499%
Growth
Revenue Growth0.13%
Earnings Growth-0.51%
Estimates
Forward P/E11.67
Forward EPS5.91
Target Mean Price72.00
Dividend
Dividend Yield1.36%
Annual dividends0.93 USD
Ex-Div. DateNov. 13, 2026
Payout60.82%

DCF valuation

Model fair value for Royalty Pharma plc (RPRX)
Result
Sign in to run the valuation for RPRX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus Buy · mean target 72.00 USD (low 66.00, high 78.00) · as of 12 Nov 2026
Low 66.00
Mean 72.00
High 78.00
Price 69.31
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Royalty Pharma plc Logo Royalty Pharma plc Analysis (RPRX)

United States Health Care Official Website Stock

Is Royalty Pharma plc a good investment? Royalty Pharma plc (RPRX) is currently trading at 69.31 USD. Market analysts have a consensus price target of 72.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 45.08. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Royalty Pharma plc is expected to release its next earnings report on Feb. 10, 2027. The market consensus estimate for Forward EPS is 5.91.

For income investors, Royalty Pharma plc pays a dividend yield of 1.36%. With a payout ratio of 61%, the dividend appears sustainable.

Investor FAQ

Does Royalty Pharma plc pay a dividend?

Yes, it pays an annual dividend of 0.93 USD (1.36% yield).

What asset class is Royalty Pharma plc?

Royalty Pharma plc is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 10, 2027. The company currently has a trailing EPS of 1.53.

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Exchange Ticker
MUN (Germany) RPD.MU
MEX (Mexico) RPRXN.MX
NMS (United States) RPRX
Trades
Dividend Yield
1.36%
Annual Dividends
0.93USD
Next Ex. Div Date
Nov. 13, 2026
Payout Ratio
60.82%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
0.76 USD
Sept. 15, 2027 (estimated) 0.2558
June 15, 2027 (estimated) 0.2523
March 15, 2027 (estimated) 0.2523
▸2026
0.94 USD
Dec. 10, 2026 0.2350
Sept. 10, 2026 0.2350
June 10, 2026 0.2350
March 10, 2026 0.2350
▸2025
0.88 USD
Dec. 10, 2025 0.2200
Sept. 10, 2025 0.2200
June 10, 2025 0.2200
March 10, 2025 0.2200
▸2024
0.84 USD
Dec. 10, 2024 0.2100
Sept. 13, 2024 0.2100
June 14, 2024 0.2100
March 15, 2024 0.2100
▸2023
0.80 USD
Dec. 15, 2023 0.2000
Sept. 15, 2023 0.2000
June 15, 2023 0.2000
March 15, 2023 0.2000
▸2022
0.76 USD
Dec. 15, 2022 0.1900
Sept. 15, 2022 0.1900
June 15, 2022 0.1900
March 15, 2022 0.1900
▸2021
0.68 USD
Dec. 15, 2021 0.1700
Sept. 15, 2021 0.1700
June 15, 2021 0.1700
March 15, 2021 0.1700
▸2020
0.30 USD
Dec. 15, 2020 0.1500
Sept. 30, 2020 0.1500
Upcoming Dividends
Name Payment Date Status Amount
Royalty Pharma plc Dec 10, 2026 Upcoming 0.235 USD
Royalty Pharma plc Sep 10, 2026 0.235 USD
Royalty Pharma plc Jun 10, 2026 0.235 USD
Royalty Pharma plc Mar 10, 2026 0.235 USD
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion